Jane Street’s Liminatus Pharma LIMN Stock Holding History

Jane Street’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,426	Closed	-$12.3K	–	13640
2026 Q1	$12.3K	Buy	+1,426	New	+$38K	﹤0.01%	11284
2025 Q4	–	Sell	-793	Closed	-$66.2K	–	12853
2025 Q3	$66.2K	Buy	+793	New	+$171K	﹤0.01%	10268

Other funds holding LIMN

CCA

Cygnus Capital Advisors Atlanta, Georgia $147M AUM

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street's LIMN Position: Q2 2026 in Review

Jane Street sold out of Liminatus Pharma (LIMN) in Q2 2026, closing a stake of 1,426 shares — an estimated $12.3K sold.

Jane Street first reported a position in LIMN in Q3 2025 and held it in 2 quarters. The position peaked at $66.2K in Q3 2025. 14 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

Jane Street reported no remaining Liminatus Pharma position as of Q2 2026 after selling out during the quarter.
Jane Street sold 1,426 Liminatus Pharma shares in Q2 2026, an estimated $12.3K.
Jane Street first reported a position in Liminatus Pharma in Q3 2025 and held it in 2 quarters.
Jane Street's Liminatus Pharma position peaked at $66.2K in Q3 2025.
14 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.